U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07653451) titled 'Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer' on June 12.
Brief Summary: This study is an open-label, biomarker-integrated umbrella trial designed to evaluate the clinical efficacy of molecular subtype- and genomic biomarker-guided precision therapies in patients with advanced esophageal cancer refractory to prior immunotherapy. Conducted in a two-step process, the study first enrolls patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed on prior immunotherapy, performing circulating tumor DNA (ctDNA) sequencing to stratify them into three distinct tre...